Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sorafenib Treatment Modalities for Hepatocellular Carcinoma Patients in Italy

Next Previous
Trial Profile

Sorafenib Treatment Modalities for Hepatocellular Carcinoma Patients in Italy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms STELLA
  • Sponsors Bayer

Most Recent Events

  • 19 Oct 2016 Results (n=512) of a pooled analysis from the Italian subgroup of GIDEON and from STELLA study assessing safety and efficacy in clinical practice, presented at the 24th United European Gastroenterology Week
  • 29 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 04 Mar 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top